Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin study group HD14 trial

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 907-913

  Von Tresckow, Bastian ^a   Plütschow, Annette ^a   Fuchs, Michael ^a   Klimm, Beate ^a   Markova, Jana ^f   Lohri, Andreas ^h   Kral, Zdenek ^g   Greil, Richard ⁱ   Topp, Max S ^b   Meissner, Julia ^c   Zijlstra, Josée M ^j   Soekler, Martin ^d   Stein, Harald ^e   Eich, Hans T ^k   Mueller, Rolf P ^a   Diehl, Volker ^a   Borchmann, Peter ^a   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^h Kantonsspital Liestal   (Switzerland)

ⁱ UNIVERSITY OF SALZBURG   (Austria)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CARDIOTOXICITY; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; GERMANY; HAIR LOSS; HODGKIN DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT FAILURE; UROGENITAL TRACT DISEASE; VOMITING; ADOLESCENT; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMORADIOTHERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 84860626866     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.5807     Document Type: Article

References (22)

1. Ferme C, Eghbali H, Meerwaldt JH, et al: Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357:1916-1927, 2007 (Pubitemid 350074687)
2. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003 (Pubitemid 46594052)
3. Noordijk EM, Carde P, Dupouy N, et al: Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135, 2006 (Pubitemid 46638951)
4. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
5. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28: 4199-4206, 2010
6. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
7. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
8. Pocock SJ: Clinical Trials: A Practical Approach. Hoboken, NJ, John Wiley and Sons, 1983
9. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977
10. Jennison C, Turnbull BW: Interim analyses: The repeated confidence interval approach. J R Stat Soc B 51:305-361, 1989
11. Ferme C, Divine M, Vranovsky A, et al: Four ABVD and involved-field radiotherapy in unfavorable supradia-phragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial. Blood 106, 2005 (abstr 813)
12. Hasenclever D, Brosteanu O, Gerike T, et al: Modelling of chemotherapy: The effective dose approach. Ann Hematol 80:B89-B94, 2001 (suppl 3)
13. Borchmann P, Engert A: The past: What we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010:101-107, 2010
14. Josting A, Müller H, Borchmann P, et al: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 28:5074-5080, 2010
15. Behringer K, Thielen I, Mueller H, et al: Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol [epub ahead of print on January 6, 2012]
16. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006 (Pubitemid 43053523)
17. Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885, 2010
18. De Bruin ML, Sparidans J, van't Veer MB, et al: Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol 27:4239-4246, 2009
19. Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112: 3989-3994, 2008
20. Girinsky T, van der Maazen R, Specht L, et al: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79:270-277, 2006 (Pubitemid 44109907)
21. Eich HT, Müller RP, Engenhart-Cabillic R, et al: Involved-node radiotherapy in early-stage Hodgkin's lymphoma: Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406-410, 2008
22. Raemaekers J: EORTC/GELA/IIL Randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with stages I/II Hodgkin's lymphoma. Presented at the 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 24-26, 2010